Novartis Ends BioArctic Brain Delivery Program
BioArctic disclosed at 21:30 CET on November 2 that Novartis will terminate the companies’ August 2025 option, collaboration, and license agreement for an undisclosed antibody using BioArctic’s transferrin-receptor BrainTransporter delivery technology. This is a…
